Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

Schjoedt, K J; Astrup, A S; Persson, F; Frandsen, E; Boomsma, F; Rossing, K; Tarnow, L; Rossing, P; Parving, H-H

Schjoedt, K J; Astrup, A S; Persson, F; Frandsen, E; Boomsma, F; Rossing, K; Tarnow, L; Rossing, P; Parving, H-H.

Affiliation

Schjoedt KJ; Steno Diabetes Center, Gentofte, Denmark. kjos@steno.dk

Diabetologia ; 52(1): 46-9, 2009 Jan.

Article in En | MEDLINE | ID: mdl-18974967

Subject(s)

Diabetic Nephropathies/drug therapy; Lisinopril/therapeutic use; Adult; Albuminuria/drug therapy; Antihypertensive Agents/therapeutic use; Cross-Over Studies; Diabetes Mellitus, Type 1/drug therapy; Diabetes Mellitus, Type 1/physiopathology; Diabetic Angiopathies/drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate/drug effects; Humans; Male; Middle Aged; Protective Agents/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lisinopril / Diabetic Nephropathies Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Diabetologia Year: 2009 Document type: Article Affiliation country: Denmark

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google